Xtant Medical Holdings Inc (XTNT) 13F Investor Activity Report (Q2 2026)

XTNT ranks #7325 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

XTNT is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

32 institutions disclose a position in XTNT, but none treat it as a major bet — even Nantahala Capital Management, LLC, its most concentrated holder, allocates just 1.0% of its own portfolio to it.

Tower Research Capital LLC has added to its XTNT position for two straight quarters, increasing it by $759.0 to reach $4.4K today.

Nantahala Capital Management, LLC has trimmed its XTNT position for two straight quarters, cutting it by $24.8M while still holding $28.8M.

XTNT reported a net loss of $11.1M over the trailing twelve months.

• Not yet profitable — net loss of $11.1M over the trailing twelve months
• Revenue declined 14.3% year over year
• Net income declined year over year, from -$4.6M to -$11.1M
• Generated $12.5M in positive operating cash flow
• Current ratio of 2.65x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.85x equity — within a conventional range